Search

Your search keyword '"Viqueira, Andrea"' showing total 76 results

Search Constraints

Start Over You searched for: Author "Viqueira, Andrea" Remove constraint Author: "Viqueira, Andrea" Publication Type Academic Journals Remove constraint Publication Type: Academic Journals
76 results on '"Viqueira, Andrea"'

Search Results

2. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

4. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial

7. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study

12. Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study

21. MM-374 Efficacy and Safety of Elranatamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Prior B-Cell Maturation Antigen (BCMA)-Directed Therapies: Pooled Analysis From MagnetisMM Studies

22. MM-364 Elranatamab, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, for Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Extended Follow-Up and Biweekly Administration From the MagnetisMM-3 Study

24. POSTER: MM-364 Elranatamab, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, for Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Extended Follow-Up and Biweekly Administration From the MagnetisMM-3 Study

25. POSTER: MM-374 Efficacy and Safety of Elranatamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Prior B-Cell Maturation Antigen (BCMA)- Directed Therapies: Pooled Analysis From MagnetisMM Studies

28. An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia.

29. A Phase I/II Study of Bosutinib in Pediatric Patients with Resistant/Intolerant or Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia, Study ITCC (Innovative Therapies for Children with Cancer European Consortium) 054 and COG (Children's Oncology Group Consortium) AAML1921: Results from the Phase I Trial in Resistant/Intolerant Patients

34. S196: ELRANATAMAB, A B‐CELL MATURATION ANTIGEN (BCMA)‐CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM MAGNETISMM‐3.

36. Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial

47. P870: EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES.

Catalog

Books, media, physical & digital resources